Stocks & ETFs

Darden Restaurants Target Raised by RBC

Darden Restaurants Target Raised by RBC

June 28, 2017 at 11:37 am 0 comments

Darden Restaurants received a price-target increase Wednesday from RBC Capital Markets after the firm updated its model on the restaurant company to reflect the addition of Cheddar’s Scratch Kitchen. The new price target is $96 per share, up from $86. The boost brings the price target above the stock’s Tuesday closing price of $92.69 from below it. RBC kept itsRead More

bluebird bio Reports Early Phase 3 Data

bluebird bio Reports Early Phase 3 Data

June 23, 2017 at 10:43 am 0 comments

Shares of bluebird bio were off 5% pre-market Friday after the company unveiled early interim data from an ongoing phase 3 trial of its blood disorder gene therapy LentiGlobin in patients with beta-thalassemia. The company said a first patient achieved a normal level of hemoglobin in six months but added a follow-up on a second and third patient was notRead More

XBiotech Shares Higher

XBiotech Shares Higher

June 1, 2017 at 11:38 am 0 comments

XBiotech (XBIT) shares were 9% higher Thursday after the company said its phase 3 study on colorectal cancer patients treated with Hutruo, or MABp1, showed improved clinical outcomes, including reduced disease progression and improved survival for those patients that achieved primary endpoint. The company said that in the study, 82% of all patients that received at least one dose ofRead More

Cardiome Pharma Amends Term-Loan Agreement with CRG

Cardiome Pharma Amends Term-Loan Agreement with CRG

May 15, 2017 at 3:19 pm 0 comments

Cardiome Pharma said early Monday it has amended its term-loan agreement with CRG-managed funds originally entered into last June. The amended agreement now provides Cardiome with up to $50 million of available borrowing capacity. The amended loan matures on March 31, 2022. The revised agreement bears interest at 13% per annum. Interest payments may be split, at the company’s option,Read More

BioTime Presents New Data on OpRegen

BioTime Presents New Data on OpRegen

May 9, 2017 at 1:04 pm 0 comments

BioTime shares were more than 2% higher in pre-market trading following the presentation of new data from the company’s phase I/IIa clinical trial of OpRegen for the treatment of advanced dry age-related macular degeneration. The results were presented Monday at the annual meeting of the Association for Research in Vision and Ophthalmology in Baltimore. Imaging analysis suggests the transplanted OpRegenRead More

FormFactor Tops Estimates

FormFactor Tops Estimates

May 4, 2017 at 12:38 pm 0 comments

FormFactor rallied 21.5%, earlier hitting the highest level since April 2010, after the company said late Wednesday Q1 sales surged to $128.8 million from $53.6 million and topped the CapIQ mean for $124.1 million. Non-GAAP EPS swung to a profit of $0.24 from a loss of $0.11 last year and beat expectations for a profit of $0.20. Q2 sales areRead More

Ryman Hospitality Properties Q1 Results Top Street Estimates

Ryman Hospitality Properties Q1 Results Top Street Estimates

May 2, 2017 at 11:08 am 0 comments

Ryman Hospitality Properties reported Tuesday Q1 funds from operations of $1.17 per share, up from $1.07 per share in the prior year period and came in higher than the $1.12 per share Street estimate provided by Capital IQ. Revenues were $276 million, up from $261.5 million reported for the same period last year and came in higher than the $270.2Read More